Latham & Watkins is geared to support emerging companies in the technology and life sciences sectors in their formation and an array of venture financing structures. The team leverages its strong national and global offering and is highly sought after by venture capital firms and financial institutions investing in companies across all stages in the lifecycle. Benjamin Potter is highly regarded for his activity advising companies in growth industries, including fintech. He leads the team alongside Brian Patterson, who has accrued significant experience assisting companies and investment funds on transactional investments in the AI sector, and Haim Zaltzman, who splits his time between San Francisco and New York. Seth Gottlieb exhibits proficiency in both corporate transactions and IPOs. Jana Kovich in Chicago is proficient in the full suite of financing and exit planning mandates. Alex Kassai is trusted by high-growth companies at all stages of maturity, with a track record in public offerings. Todd Trattner joined from Gibson, Dunn & Crutcher LLP in October 2025.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- The highest expertise and trust levels of any legal firm in the United States. There is a lot of depth and breadth across several areas of law. Fast response times and easy collaboration.
- Benjamin Potter: The singular reason why I work with LW.
Key clients
- Abridge AI
- Black Rock Coffee Bar
- Blocq
- Brookfield Asset Management
- ButterflyMX
- Character Biosciences
- Cosmic
- General Catalyst Partners
- Groundfloor Finance
- Kandji
- OfferFit
- Oura Ring
Work highlights
Advised Abridge, the leading generative AI platform for clinical conversations, in its US$300 million Series E funding and US$250 million Series D funding.
Represented Oura Ring, maker of the smart ring that delivers personalized health data, insights, and daily guidance, in its US$200 million Series D financing.
Advised Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, in its US$93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases, starting with age-related macular degeneration (AMD).
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Benjamin Potter; Brian C. Patterson; Haim Zaltzman
Other key lawyers
Seth Gottlieb; Alex Kassai; Todd Trattner; Scott Craig